I propose to take Questions Nos. 676, 808, 823 and 875 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
I am advised that commercial discussions between the HSE and the manufacturer on extending the availability of Kaftrio to these children are at a very sensitive stage. It would therefore not be appropriate to comment at this time as to the status of these discussions as I would not wish to jeopardise the ongoing process.
However, I can assure the that this matter is being expedited at speed and is receiving all the necessary attention.